SNRNP200 and acute myeloid leukemia: Given the limited clinical success with any single-agent therapy for overt AML, we also investigated the therapeutic impact of combining the IgG2a anti-U5 snRNP200 antibody with a commonly used therapeutic for patients with AML: the nucleoside analog azacitidine.